Cargando…

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors

The number of people living with type 2 diabetes (T2D) and its complications worldwide is increasing at an alarming rate. Fortunately, our understanding of the benefits of glucose-lowering agents from the sodium–glucose co-transporter-2 (SGLT2) inhibitor and glucagon-like peptide-1 (GLP-1) receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neumiller, Joshua J, Lienhard, Fredrick J, Alicic, Radica Z, Tuttle, Katherine R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Touch Medical Media 2022
Materias:	Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835817/ https://www.ncbi.nlm.nih.gov/pubmed/36694888 http://dx.doi.org/10.17925/EE.2022.18.2.106

Ejemplares similares

Erratum. Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 2019;68:248–257
por: Alicic, Radica Z., et al.
Publicado: (2019)

Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
por: Alicic, Radica Z., et al.
Publicado: (2023)

Use of Glucose-Lowering Agents in Diabetes and CKD
por: Alicic, Radica Z., et al.
Publicado: (2022)

Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney
por: Tuttle, Katherine R., et al.
Publicado: (2021)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Medication use, renin–angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease
por: Neumiller, Joshua J, et al.
Publicado: (2020)

Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry
por: Tuttle, Katherine R., et al.
Publicado: (2019)

Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths
por: Dieter, Brad P., et al.
Publicado: (2015)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD
por: Norris, Keith C., et al.
Publicado: (2019)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Perspectives on Chronic Kidney Disease With Type 2 Diabetes and Risk Management: Practical Viewpoints and a Paradigm Shift Using a Pillar Approach
por: Morales, Javier, et al.
Publicado: (2023)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
por: Jain, Rajesh, et al.
Publicado: (2022)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Use of Continuous Glucose Monitoring in Older Adults: A Review of Benefits, Challenges and Future Directions
por: Prasad-Reddy, Lalita, et al.
Publicado: (2022)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

ODP252 Urosepsis and Sodium-Glucose Co-Transporter-2 Inhibitors: A Systematic Review and Meta-Analysis
por: Prasongdee, Klaorat, et al.
Publicado: (2022)

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
por: Tuttle, Katherine R., et al.
Publicado: (2021)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study
por: Baruah, Manash P, et al.
Publicado: (2019)

Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis
por: Chen, Min, et al.
Publicado: (2016)

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
por: Xu, Lubin, et al.
Publicado: (2017)

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
por: Beitelshees, Amber L., et al.
Publicado: (2019)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

RF16 | PSUN335 Clinical Effects of Sodium Glucose Transporter Type 2 Inhibitors in Patients with Severe Insulin Resistance
por: Bansal, Rashika, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023)

Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
por: Mannucci, Edoardo, et al.
Publicado: (2013)

COVID-19 and Gastrointestinal Tract Symptoms: Recognition, Containment, and Learning From the Past
por: McDermott, Carmen V., et al.
Publicado: (2020)

In Reply — Neutralization of Fecal Aerosol-Laden SARS CoV-2: Public Health Implications
por: McDermott, Carmen V., et al.
Publicado: (2021)

Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review
por: Kapila, Vaishali, et al.
Publicado: (2021)

MON-639 Melanocortin 4 Receptor Contributes to Glucose Homeostasis by Regulating Kidney Glucose Reabsorption via the Glucose Transporter GLUT2
por: de Souza Cordeiro, Leticia M, et al.
Publicado: (2020)

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bok764incua5daujkndko4gpdo